The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT).
 
Nabil Adra
Research Funding - Genentech (Inst); Merck (Inst)
 
Sandra K. Althouse
No Relationships to Disclose
 
Hao Liu
No Relationships to Disclose
 
Rafat Abonour
No Relationships to Disclose
 
Mohammad Issam Abu Zaid
No Relationships to Disclose
 
Clint Cary
No Relationships to Disclose
 
Timothy A. Masterson
No Relationships to Disclose
 
Richard Foster
No Relationships to Disclose
 
Costantine Albany
Stock and Other Ownership Interests - Advaxis
Honoraria - Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Seagen
Speakers' Bureau - Bayer; Sanofi
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Nasser H. Hanna
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck KGaA (Inst)
 
Lawrence H. Einhorn
Stock and Other Ownership Interests - Amgen; Biogen
Consulting or Advisory Role - Celgene